Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies

Area of Science:

• Immunology
• Hematology
• Vascular Medicine

Background:

• Antiphospholipid antibodies (aPL) are a significant cause of arterial and venous thromboembolic events, including stroke.
• Standardized tests for aPL (anticardiolipin antibodies [aCL] by ELISA and lupus anticoagulant [LA] by coagulometric assays) are available.
• aPL testing is routinely performed in patients with systemic lupus erythematosus (SLE), connective tissue diseases, and women with recurrent pregnancy loss.

Purpose of the Study:

• To investigate the clinical implications and management strategies for individuals testing positive for antiphospholipid antibodies (aPL) but without a history of thrombosis.
• To address the knowledge gap regarding the thrombotic risk in aPL-positive individuals who are currently asymptomatic for thrombosis.

Main Methods:

• Standardized immunoassays (ELISA) for anticardiolipin antibodies (aCL).
• Coagulometric assays for lupus anticoagulant (LA) detection.
• Review of existing literature and clinical guidelines concerning aPL and thrombosis.

Main Results:

• The presence of aPL is a well-established risk factor for thromboembolic disease.
• Current diagnostic criteria and testing methodologies for aPL are standardized and widely implemented.
• There is a lack of established treatment protocols for aPL-positive individuals without a history of thrombosis.

Conclusions:

• Identifying individuals with aPL but no thrombosis is clinically feasible.
• The thrombotic risk and optimal management for this specific cohort remain largely undetermined.
• Further research is crucial to establish evidence-based treatment guidelines for aPL-positive, thrombosis-free individuals.